Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning - PubMed (original) (raw)

Clinical Trial

. 2007 Feb;60(2 Suppl 1):ONS89-98; discussion ONS98-9.

doi: 10.1227/01.NEU.0000249256.09289.5F.

Affiliations

• PMID: 17297371
• DOI: 10.1227/01.NEU.0000249256.09289.5F

Clinical Trial

Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning

John H Sampson et al. Neurosurgery. 2007 Feb.

Abstract

Objective: Convection-enhanced delivery (CED) holds tremendous potential for drug delivery to the brain. However, little is known about the volume of distribution achieved within human brain tissue or how target anatomy and catheter positioning influence drug distribution. The primary objective of this study was to quantitatively describe the distribution of a high molecular weight agent by CED relative to target anatomy and catheter position in patients with malignant gliomas.

Methods: Seven adult patients with recurrent malignant gliomas underwent intracerebral infusion of the tumor-targeted cytotoxin, cintredekin besudotox, concurrently with 123I-labeled human serum albumin. High-resolution single-photon emission computed tomographic images were obtained at 24 and 48 hours and were coregistered with magnetic resonance imaging scans. The distribution of 123I-labeled human serum albumin relative to target anatomy and catheter position was analyzed.

Results: Intracerebral CED infusions were well-tolerated and some resulted in a broad distribution of 123I-labeled human serum albumin, but target anatomy and catheter positioning had a significant influence on infusate distribution even within non-contrast-enhancing areas of brain. Intratumoral infusions were anisotropic and resulted in limited coverage of the enhancing tumor area and adjacent peritumoral regions.

Conclusions: CED has the potential to deliver high molecular weight agents into tumor-infiltrated brain parenchyma with volumes of distribution that are clinically relevant. Target tissue anatomy and catheter position are critical parameters in optimizing drug delivery.

PubMed Disclaimer

Similar articles

• Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
  Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH, Pedain C, Puri RK. Kunwar S, et al. Neurosurg Focus. 2006 Apr 15;20(4):E15. Neurosurg Focus. 2006. PMID: 16709020 Clinical Trial.
• Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.
  Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, Rodríguez Ponce I, Pastan I, Puri RK, Pedain C. Sampson JH, et al. AJR Am J Roentgenol. 2007 Mar;188(3):703-9. doi: 10.2214/AJR.06.0428. AJR Am J Roentgenol. 2007. PMID: 17312057
• Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
  Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group. Kunwar S, et al. J Clin Oncol. 2007 Mar 1;25(7):837-44. doi: 10.1200/JCO.2006.08.1117. J Clin Oncol. 2007. PMID: 17327604 Clinical Trial.
• Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
  Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK. Kioi M, et al. Technol Cancer Res Treat. 2006 Jun;5(3):239-50. doi: 10.1177/153303460600500307. Technol Cancer Res Treat. 2006. PMID: 16700620 Review.
• Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors.
  Ferguson S, Lesniak MS. Ferguson S, et al. Curr Drug Deliv. 2007 Apr;4(2):169-80. doi: 10.2174/156720107780362302. Curr Drug Deliv. 2007. PMID: 17456036 Review.

Cited by

• Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum.
  Osting S, Bennett A, Power S, Wackett J, Hurley SA, Alexander AL, Agbandje-Mckena M, Burger C. Osting S, et al. Mol Ther Methods Clin Dev. 2014 Jan 8;1:4. doi: 10.1038/mtm.2013.4. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015943 Free PMC article.
• Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
  Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE 2nd, Croteau D, Friedman AH, Reardon DA, Coleman RE, Wong T, Bigner DD, Pastan I, Rodríguez-Ponce MI, Tanner P, Puri R, Pedain C. Sampson JH, et al. Neuro Oncol. 2007 Jul;9(3):343-53. doi: 10.1215/15228517-2007-007. Epub 2007 Apr 13. Neuro Oncol. 2007. PMID: 17435179 Free PMC article. Clinical Trial.
• Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain.
  Idema S, Caretti V, Lamfers ML, van Beusechem VW, Noske DP, Vandertop WP, Dirven CM. Idema S, et al. PLoS One. 2011;6(10):e24396. doi: 10.1371/journal.pone.0024396. Epub 2011 Oct 13. PLoS One. 2011. PMID: 22022354 Free PMC article.
• The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.
  Perez JG, Tran NL, Rosenblum MG, Schneider CS, Connolly NP, Kim AJ, Woodworth GF, Winkles JA. Perez JG, et al. Oncogene. 2016 Apr 28;35(17):2145-55. doi: 10.1038/onc.2015.310. Epub 2015 Aug 24. Oncogene. 2016. PMID: 26300004 Free PMC article. Review.
• Convection Enhanced Delivery of Topotecan for Gliomas: A Single-Center Experience.
  Upadhyayula PS, Spinazzi EF, Argenziano MG, Canoll P, Bruce JN. Upadhyayula PS, et al. Pharmaceutics. 2020 Dec 30;13(1):39. doi: 10.3390/pharmaceutics13010039. Pharmaceutics. 2020. PMID: 33396668 Free PMC article. Review.

Publication types

MeSH terms

Substances

Grants and funding

• 2P50-NS20023/NS/NINDS NIH HHS/United States
• 5P50-CA108786/CA/NCI NIH HHS/United States
• K23 RR16065/RR/NCRR NIH HHS/United States
• R01 CA097611/CA/NCI NIH HHS/United States
• S10 RR15697/RR/NCRR NIH HHS/United States
• Intramural NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information